Core Insights - Henry Schein (HSIC) reported quarterly earnings of $1.38 per share, exceeding the Zacks Consensus Estimate of $1.27 per share, and up from $1.22 per share a year ago, representing an earnings surprise of +8.66% [1] - The company posted revenues of $3.34 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.02% and increasing from $3.17 billion year-over-year [2] - The stock has underperformed the market, losing about 6.6% since the beginning of the year compared to the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.31 on revenues of $3.3 billion, and for the current fiscal year, it is $4.82 on revenues of $12.98 billion [7] - The estimate revisions trend for Henry Schein was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Dental Supplies industry, to which Henry Schein belongs, is currently in the top 23% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Q2 2025 Financial Performance - Total sales increased by 3.3% to $3.24 billion[18, 54] - Global Distribution and Value-Added Services Group sales grew by 2.4%[15] - Global Specialty Products Group sales increased by 3.3%[15] - Global Technology Group sales grew by 6.6%[15] - Non-GAAP diluted EPS was $1.10, compared to $1.23 in Q2 2024[15] - Adjusted EBITDA was $256 million, compared to $268 million in Q2 2024, a decrease of 4.8%[15, 18] Full Year 2025 Guidance - The company maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94[12, 46] - Adjusted EBITDA is expected to grow in the mid-single digits versus 2024 Adjusted EBITDA of $1.1 billion[46] - Total sales growth is projected to be between 2% and 4%[12, 48] Capital Allocation - $32 million was invested in capital expenditures in Q2[39] - $50 million was invested in acquisitions in Q2[39] - $259 million was used for share repurchases in Q2[39]

Core Insights - Medical equipment distributor Henry Schein raised its annual profit forecast after exceeding Wall Street estimates for third-quarter results [1] - The strong performance was driven by robust sales in both dental and medical segments [1] Financial Performance - Henry Schein reported third-quarter results that surpassed analyst expectations, indicating a positive trend in sales [1] - The company’s updated profit forecast reflects confidence in continued growth and market demand [1] Market Segments - Sales growth was particularly strong in the dental sector, contributing significantly to overall performance [1] - The medical segment also showed strong sales, highlighting the diversified nature of the company’s revenue streams [1]

Financial Performance - Q3 2025 GAAP diluted EPS was $0.84, up from $0.78 in Q3 2024; non-GAAP diluted EPS was $1.38, compared to $1.22 in Q3 2024[5] - Total net sales for Q3 2025 reached $3.3 billion, a 5.2% increase compared to Q3 2024, driven by 3.3% internal sales growth, 0.7% from acquisitions, and 1.2% from foreign currency exchange[6] - The company raised its 2025 non-GAAP diluted EPS guidance to $4.88 to $4.96, reflecting a year-over-year growth of 3% to 5%[15] - Adjusted EBITDA for Q3 2025 was $295 million, compared to $268 million in Q3 2024[8] - Net income attributable to Henry Schein, Inc. for Q3 2025 was $101 million, compared to $99 million in Q3 2024, showing a 2% increase[33] - Year-to-date net income for 2025 reached $316 million, compared to $302 million in the same period of 2024[52] - Year-to-date Adjusted EBITDA for 2025 totaled $810 million, compared to $791 million in 2024, indicating a growth of about 2.4%[52] Sales Growth - Total net sales for the first nine months of 2025 were $9.7 billion, a 2.8% increase compared to the same period in 2024[8] - Global Technology sales increased by 9.7% in Q3 2025, reflecting accelerated adoption of cloud-based software and new revenue cycle management solutions[6] - Global Dental Distribution merchandise sales increased by 4.6% in Q3 2025 compared to Q3 2024, indicating consistent growth across U.S. and international markets[8] - Total Global Distribution and Value-Added Services sales for Q3 2025 were $8,247 million, a 1.4% increase from $8,058 million in Q3 2024[44] - Medical segment sales in the U.S. rose by 3.2% to $3,117 million in Q3 2025[44] - Global Specialty Products sales increased by 2.3% to $1,122 million in Q3 2025[44] Shareholder Actions - The company repurchased approximately 3.3 million shares of common stock for a total of $229 million during Q3 2025[9] - The board approved an amendment allowing KKR to increase its ownership in HSIC stock up to 19.9%[12] Assets and Liabilities - Total current assets increased to $4,395 million as of September 27, 2025, compared to $3,983 million at the end of December 2024[36] - Total assets grew to $11,097 million as of September 27, 2025, up from $10,218 million at the end of December 2024[36] - Total liabilities increased to $6,197 million as of September 27, 2025, compared to $5,381 million at the end of December 2024[36] - Cash and cash equivalents at the end of Q3 2025 were $136 million, compared to $126 million at the end of Q3 2024[38] Operating Income and Expenses - Operating income for Q3 2025 increased to $164 million, compared to $157 million in Q3 2024, representing a 4.5% growth[33] - Interest expense increased to $38 million in Q3 2025 from $34 million in Q3 2024[52] - Restructuring costs for Q3 2025 were $34 million, down from $48 million in Q3 2024, showing a reduction of approximately 29.2%[52] - Costs associated with shareholder advisory matters and select value creation consulting costs amounted to $10 million in Q3 2025[52] - Depreciation and amortization expenses for Q3 2025 were $80 million, an increase from $74 million in Q3 2024[52] Value Creation Initiatives - Value creation initiatives are expected to deliver over $200 million in operating income improvements over the next few years[5]

Core Insights - Henry Schein, Inc. (HSIC) is set to announce its third-quarter 2025 results on November 4, with previous adjusted EPS of $1.10 missing estimates by 6.78% [1] - The Zacks Consensus Estimate anticipates revenues of $3.27 billion, reflecting a 3.1% year-over-year increase, and an EPS of $1.27, indicating a 4.1% improvement [2] Q3 Estimates for HSIC - Revenue estimates for the third quarter have been set at $3.27 billion, which is a 3.1% increase from the previous year [2] - EPS estimates are projected at $1.27, showing a year-over-year growth of 4.1% [2] Estimate Revision Trend - Earnings estimates for the third quarter have decreased by 1 cent over the past 30 days [3] Factors Influencing Performance - The Global Distribution and Value-Added Services segment is expected to show strong volume growth in the U.S. Dental Merchandise business, aided by improved average selling prices [4] - International performance, particularly in Brazil, is anticipated to be favorable, with U.S. Dental Equipment sales recovering from tariff-related uncertainties [4] - The Value-Added Services segment may benefit from the high-margin Practice Transitions business, while the U.S. Global Medical business is likely to see increased sales of medical products and pharmaceuticals [5] Revenue Projections - Global Distribution and Value-Added Services revenues are projected to rise by 2.1% year-over-year in the third quarter [6] - The Specialty Products segment is expected to achieve a 4.2% year-over-year revenue increase, driven by strong sales of dental implants and biomaterials [9] - Global Technology revenues are anticipated to grow by 7.4% year-over-year, supported by cloud and SaaS offerings [10] Earnings ESP and Zacks Rank - Henry Schein currently has an Earnings ESP of -0.35%, indicating a lower likelihood of beating estimates [11] - The company holds a Zacks Rank of 4 (Sell) [12]

Company Overview - Henry Schein, Inc. is the world's largest provider of health care solutions to office-based dental and medical practitioners, offering over 300 valued solutions to more than 1 million customers globally [2][4] - The company operates through a centralized and automated distribution network, providing a selection of more than 300,000 branded products and corporate brand products [3] - Henry Schein is a FORTUNE 500 Company and a member of the S&P 500 index, with operations or affiliates in 33 countries and territories [4] Financial Performance - The company's sales reached $12.7 billion in 2024, growing at a compound annual rate of approximately 11.2 percent since becoming a public company in 1995 [4] Upcoming Events - Henry Schein will participate in investor conferences in November, including the Stifel's Healthcare Conference on November 12, 2025, and the Jefferies Healthcare Conference on November 18, 2025 [6] - The company will also webcast its third quarter 2025 financial results on November 4, 2025, at 8:00 A.M. Eastern time [9]

Group 1 - Henry Schein, Inc. will release its third quarter 2025 financial results before the stock market opens on November 4, 2025 [1] - A live webcast of the earnings conference call will take place on the same day at 8:00 a.m. Eastern time [1] - Stanley M. Bergman, Chairman of the Board, will be among the speakers on the call [1]

Macro Environment Overview - The macro environment in the dental industry has remained relatively stable, with patient traffic data indicating consistent levels throughout the year [1] - Patient traffic is considered a key indicator for merchandise sales and inventory turnover [1] Impact of Interest Rate Changes - The recent cuts in U.S. interest rates are viewed as a significant macroeconomic factor that may provide short-term opportunities for increased equipment sales [2] - Larger dollar equipment sales are often financed through leasing or other financing methods, suggesting potential for growth in this area due to lower interest rates [2]

Summary of Henry Schein 2025 Conference Call Company Overview - **Company**: Henry Schein (NasdaqGS: HSIC) - **Date of Conference**: September 24, 2025 Key Industry Insights - **Macro Environment**: The U.S. is experiencing a reduction in interest rates, which is expected to positively impact equipment sales and the establishment of new dental practices, particularly by Dental Service Organizations (DSOs) [4][5][22] - **Patient Traffic**: Patient traffic in dental practices has remained stable, serving as a key indicator for merchandise sales [3][4] - **International Growth**: There is a slight uptick in international business, especially in Mainland Europe, following a period of energy price increases [7] Core Company Strategies and Performance - **Sales Growth**: Promotional activities in Q2 have started to yield positive results, with double-digit growth in customer engagement and sales [11][9] - **Customer Retention**: Efforts to engage episodic customers through field sales consultants are aimed at increasing market share and customer loyalty [12][14] - **Field Sales Force**: The addition of experienced sales representatives is ongoing, with expectations of ramping up to full productivity within 12 months [15][16][17] Financial Outlook - **EPS Growth**: The company aims for high single-digit EPS growth in 2026, with various macroeconomic factors influencing this target, including interest rates and unemployment [19][20][22] - **Cost Optimization**: Henry Schein is undertaking value creation projects to optimize gross profit and general & administrative costs, with expected benefits starting in 2026 [23][25][26] Market Dynamics - **Pricing and Tariffs**: The company is navigating the impact of tariffs on private label products, which may necessitate price increases while maintaining competitiveness [31][32] - **Implant Market**: The value implant market is growing faster than the premium segment in the U.S., with DSOs increasingly adopting value implants for straightforward procedures [34][38][46] Medical Segment Insights - **Vaccine Demand**: The flu vaccine remains a significant product, with expectations for normal demand levels. The COVID vaccine is less impactful due to low margins [56][58] - **Medical Business Growth**: The medical segment has seen a 6% growth, driven by pharmaceuticals and point-of-care diagnostic kits, with a notable home health business growing at a faster pace [64][65] Technology Business Performance - **Growth Rates**: The core practice management systems are performing well, but peripheral products are dragging down overall growth. Consolidation of brands is expected to improve growth rates [66][68][70] Capital Deployment Strategy - **Share Repurchase Program**: A $750 million share repurchase program has been announced, indicating a strategic focus on capital deployment while remaining opportunistic regarding M&A [71][73] Additional Considerations - **Market Expansion**: The company is optimistic about the expansion of the market for dental practices, particularly with the potential for new practice builds as interest rates decline [5][6] - **Customer Engagement**: The focus on educating customers about profitability and operational efficiency is seen as a key driver for long-term relationships and market share growth [12][14]

Core Insights - Pearl has joined the Henry Schein One API Exchange, which indicates a strategic partnership aimed at enhancing dental practice efficiency through technology integration [1] Company Summary - Pearl is integrating its AI tools with Dentrix and Dentrix Ascend, which are platforms provided by Henry Schein One, to deliver secure artificial intelligence solutions [1] - The collaboration is expected to boost operational efficiency and improve patient care within dental practices [1]